Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 29, 2019

SELL
$217.44 - $243.88 $209,829 - $235,344
-965 Closed
0 $0
Q2 2019

Jul 26, 2019

SELL
$219.29 - $241.72 $39,691 - $43,751
-181 Reduced 15.79%
965 $226,000
Q1 2019

Apr 09, 2019

BUY
$216.71 - $338.96 $23,838 - $37,285
110 Added 10.62%
1,146 $271,000
Q4 2018

Feb 13, 2019

SELL
$278.5 - $352.75 $34,812 - $44,093
-125 Reduced 10.77%
1,036 $312,000
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $372,757 - $487,464
-1,270 Reduced 52.24%
1,161 $411,000
Q1 2018

Apr 03, 2018

SELL
$260.13 - $367.91 $26,013 - $36,791
-100 Reduced 3.95%
2,431 $666,000
Q3 2017

Oct 05, 2017

BUY
$281.15 - $329.69 $711,590 - $834,445
2,531
2,531 $793,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $20.4B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Washington Trust Bank Portfolio

Follow Washington Trust Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Trust Bank, based on Form 13F filings with the SEC.

News

Stay updated on Washington Trust Bank with notifications on news.